SCA
NVO

Strategic Capital Alternatives’s Novo Nordisk NVO Stock Holding History

Strategic Capital Alternatives’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,050
Closed -$84K – 414
2015
Q2 		$84K Buy
+3,050
New +$85.7K 0.02% 254
2014
Q4 		– Sell
-3,050
Closed -$73K – 251
2014
Q3 		$73K Buy
+3,050
New +$70.2K 0.03% 193

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Strategic Capital Alternatives's NVO Position: Q3 2015 in Review

Strategic Capital Alternatives sold out of Novo Nordisk (NVO) in Q3 2015, closing a stake of 3,050 shares — an estimated $84K sold.

Strategic Capital Alternatives first reported a position in NVO in Q3 2014 and held it in 2 quarters. The position peaked at $84K in Q2 2015. 526 funds tracked by Wall St. Rank hold NVO as of Q3 2015.

  • Strategic Capital Alternatives reported no remaining Novo Nordisk position as of Q3 2015 after selling out during the quarter.
  • Strategic Capital Alternatives sold 3,050 Novo Nordisk shares in Q3 2015, an estimated $84K.
  • Strategic Capital Alternatives first reported a position in Novo Nordisk in Q3 2014 and held it in 2 quarters.
  • Strategic Capital Alternatives's Novo Nordisk position peaked at $84K in Q2 2015.
  • 526 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.